ClinicalTrials.gg
CompletedNCT02106923Updated Mar 9, 2017Results posted

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Extended Release (XR) Compared With Single Tablets

A Phase 1 interventional study of 1 tablet Empagliflozin/2 tablets Metformin XR and 10 mg Empagliflozin/1000 mg Metformin XR in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-03-09.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The purpose of this trial is to demonstrate the relative bioavailability of 2 newly developed fixed dose combinations (FDC) tablets containing empagliflozin \& metformin XR and the single tablets of empagliflozin and metformin XR when administered singularly

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy males or females
  2. Age 18-50 years (incl.)
  3. (BMI) 18.5 to 29.9 kg/m2 (incl.)
  4. Subjects must be able to understand and comply with study requirements

Exclusion criteria

Exclusion criteria:

Any deviation from healthy condition

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    High dose, fasted

    1 fixed dose combination (FDC) tablet vs 3 single tablets under fasted conditions

    Drug: 10 mg Empagliflozin/1000 mg Metformin XR · Drug: 1 tablet Empagliflozin/2 tablets Metformin XR

  • Experimental
    High dose, fed

    1 fixed dose combination (FDC) tablet vs 3 single tablets under fed conditions

    Drug: 1 tablet Empagliflozin/2 tablets Metformin XR · Drug: 10 mg Empagliflozin/1000 mg Metformin XR

  • Experimental
    Low dose, fasted

    2 fixed dose combination (FDC) tablets vs 4 single tablets under fasted conditions

    Drug: 1 tablet 10 mg Empagliflozin/3 tablets Metformin XR · Drug: 2 tablets 5 mg Empagliflozin/750 Metformin XR

Interventions

  • Drug1 tablet Empagliflozin/2 tablets Metformin XR

    Active Comparator: 1 x Empagliflozin/2x Metformin XR tablets

  • Drug10 mg Empagliflozin/1000 mg Metformin XR

    Drug pages: Empagliflozin · Metformin

    Experimental: high dose Empagliflozin/Metformin XR, FDC tablet

  • Drug1 tablet 10 mg Empagliflozin/3 tablets Metformin XR

    Active Comparator: 1 x Empagliflozin/3 x Metformin XR tablets

  • Drug2 tablets 5 mg Empagliflozin/750 Metformin XR

    Experimental:2 x low dose Empagliflozin/Metformin XR FDC tablets

  • Drug1 tablet Empagliflozin/2 tablets Metformin XR

    Active Comparator: 1 x Empagliflozin/2x Metformin XR tablets

  • Drug10 mg Empagliflozin/1000 mg Metformin XR

    Drug pages: Empagliflozin · Metformin

    Experimental: high dose Empagliflozin/Metformin XR, FDC tablet

06

What researchers measure

Primary outcomes

  1. AUC0-tz (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point), for Empagliflozin

    Area under the concentration-time curve of empagliflozin in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz).

    Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 20min, 1h 40min, 2h, 2.5h, 3h, 4h, 5h, 6h, 7h, 8h, 9h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration

  2. AUC0-tz (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point) for Metformin

    Area under the concentration-time curve of metformin in plasma over the time interval from 0 to the last quantifiable data point

    Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 20min, 1h 40min, 2h, 2.5h, 3h, 4h, 5h, 6h, 7h, 8h, 9h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration

  3. Cmax (Maximum Measured Concentration of the Analyte in Plasma, for Empagliflozin

    Maximum measured concentration of empagliflozin in plasma (Cmax).

    Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 20min, 1h 40min, 2h, 2.5h, 3h, 4h, 5h, 6h, 7h, 8h, 9h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration

  4. Cmax (Maximum Measured Concentration of the Analyte in Plasma, for Metformin

    Maximum measured concentration of metformin in plasma

    Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 20min, 1h 40min, 2h, 2.5h, 3h, 4h, 5h, 6h, 7h, 8h, 9h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration

Secondary outcomes

  1. AUC0-infinity (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity), for Empagliflozin

    Area under the concentration-time curve of empagliflozin in plasma over the time interval from 0 extrapolated to infinity (AUC0-infinity).

    Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 20min, 1h 40min, 2h, 2.5h, 3h, 4h, 5h, 6h, 7h, 8h, 9h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration

  2. AUC0-infinity (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity), for Metformin

    Area under the concentration-time curve of metformin in plasma over the time interval from 0 extrapolated to infinity

    Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 20min, 1h 40min, 2h, 2.5h, 3h, 4h, 5h, 6h, 7h, 8h, 9h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration

07

Results

Posted Mar 9, 2017

Participant flow

Participant flow — Overall Study
MilestoneEmpa+1000mg Met FDC / Empa+1000mg Glumetza® (Fasted)Empa+1000mg Glumetza / Empa+1000mg Met FDC (Fasted)Empa+1000mg Met FDC / Empa+1000mg Glumetza (Fed)Empa+1000mg Glumetza / Empa+1000mg Met FDC (Fed)Empa+1500mg Met FDC / Empa+1500mg Glumetza (Fasted)Empa+1500mg Glumetza / Empa+1500mg Met FDC (Fasted)
Started121212121212
Completed121212121211
Not completed000001
Withdrew: Protocol violation000001

Outcome measures

PrimaryAUC0-tz (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point), for Empagliflozin

Area under the concentration-time curve of empagliflozin in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz).

Time frame:
1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 20min, 1h 40min, 2h, 2.5h, 3h, 4h, 5h, 6h, 7h, 8h, 9h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration
Reported as:
Geometric mean · nmol*h/L
AUC0-tz (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point), for Empagliflozin
nmol*h/LEmpa/1000 mg Glumetza® (Fasted)Empa/ 1000 mg Met FDC (Fasted)Empa/1000 mg Glumetza ® (Fed)Empa/ 1000 mg Met FDC (Fed)Empa/ 1500 mg Glumetza® (Fasted)Empa/ 1500 mg Met FDC (Fasted)
AUC0-tz (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point), for Empagliflozin2630 ± 18.92710 ± 18.32720 ± 20.52710 ± 19.92790 ± 17.32680 ± 18.7
Statistical analysis
  • Empa/1000 mg Glumetza® (Fasted) vs Empa/ 1000 mg Met FDC (Fasted) · ANOVA · p = <0.0001 · Adjusted geometric mean ratio (%): 102.98 · 90% CI 100.505 to 105.514Ratio calculated as Empa/ 1000 mg Met FDC (Fasted) divided by Empa/1000 mg Glumetza® (Fasted)
  • Empa/1000 mg Glumetza ® (Fed) vs Empa/ 1000 mg Met FDC (Fed) · ANOVA · p = <0.0001 · Adjusted geometric mean ratio (%): 100.25 · 90% CI 96.809 to 103.823Ratio calculated as Empa/ 1000 mg Met FDC (Fed) divided by Empa/1000 mg Glumetza ® (Fed)
  • Empa/ 1500 mg Glumetza® (Fasted) vs Empa/ 1500 mg Met FDC (Fasted) · ANOVA · p = <0.0001 · Adjusted geometric mean ratio (%): 96.08 · 90% CI 93.507 to 98.721Ratio calculated as Empa/ 1500 mg Met FDC (Fasted) divided by Empa/ 1500 mg Glumetza® (Fasted)
PrimaryAUC0-tz (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point) for Metformin

Area under the concentration-time curve of metformin in plasma over the time interval from 0 to the last quantifiable data point

Time frame:
1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 20min, 1h 40min, 2h, 2.5h, 3h, 4h, 5h, 6h, 7h, 8h, 9h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration
Reported as:
Geometric mean · ng*h/mL
AUC0-tz (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point) for Metformin
ng*h/mLEmpa/1000 mg Glumetza® (Fasted)Empa/ 1000 mg Met FDC (Fasted)Empa/1000 mg Glumetza ® (Fed)Empa/ 1000 mg Met FDC (Fed)Empa/ 1500 mg Glumetza® (Fasted)Empa/ 1500 mg Met FDC (Fasted)
AUC0-tz (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point) for Metformin7020 ± 35.27170 ± 36.213500 ± 19.113200 ± 18.89860 ± 26.410100 ± 25.6
Statistical analysis
  • Empa/1000 mg Glumetza® (Fasted) vs Empa/ 1000 mg Met FDC (Fasted) · ANOVA · p = 0.0011 · Adjusted geometric mean ratio (%): 102.04 · 90% CI 92.30 to 112.81Ratio calculated as Empa/ 1000 mg Met FDC (Fasted) divided by Empa/1000 mg Glumetza® (Fasted)
  • Empa/1000 mg Glumetza ® (Fed) vs Empa/ 1000 mg Met FDC (Fed) · ANOVA · p = <0.0001 · Adjusted geometric mean ratio (%): 98.93 · 90% CI 95.45 to 102.53Ratio calculated as Empa/ 1000 mg Met FDC (Fed) divided by Empa/1000 mg Glumetza ® (Fed)
  • Empa/ 1500 mg Glumetza® (Fasted) vs Empa/ 1500 mg Met FDC (Fasted) · ANOVA · p = 0.0002 · Adjusted geometric mean ratio (%): 101.70 · 90% CI 93.59 to 110.52Ratio calculated as Empa/ 1500 mg Met FDC (Fasted) divided by Empa/ 1500 mg Glumetza® (Fasted)
SecondaryAUC0-infinity (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity), for Empagliflozin

Area under the concentration-time curve of empagliflozin in plasma over the time interval from 0 extrapolated to infinity (AUC0-infinity).

Time frame:
1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 20min, 1h 40min, 2h, 2.5h, 3h, 4h, 5h, 6h, 7h, 8h, 9h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration
Reported as:
Geometric mean · nmol*h/L
AUC0-infinity (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity), for Empagliflozin
nmol*h/LEmpa/1000 mg Glumetza® (Fasted)Empa/ 1000 mg Met FDC (Fasted)Empa/1000 mg Glumetza ® (Fed)Empa/ 1000 mg Met FDC (Fed)Empa/ 1500 mg Glumetza® (Fasted)Empa/ 1500 mg Met FDC (Fasted)
AUC0-infinity (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity), for Empagliflozin2680 ± 18.72760 ± 17.92790 ± 21.32770 ± 20.22840 ± 17.42740 ± 19.5
Statistical analysis
  • Empa/1000 mg Glumetza® (Fasted) vs Empa/ 1000 mg Met FDC (Fasted) · ANOVA · p = <0.0001 · Adjusted geometric mean ratio (%): 102.88 · 90% CI 100.446 to 105.373Ratio calculated as Empa/ 1000 mg Met FDC (Fasted) divided by Empa/1000 mg Glumetza® (Fasted)
  • Empa/1000 mg Glumetza ® (Fed) vs Empa/ 1000 mg Met FDC (Fed) · ANOVA · p = <0.0001 · Adjusted geometric mean ratio (%): 100.03 · 90% CI 96.448 to 103.738Ratio calculated as Empa/ 1000 mg Met FDC (Fed) divided by Empa/1000 mg Glumetza ® (Fed)
  • Empa/ 1500 mg Glumetza® (Fasted) vs Empa/ 1500 mg Met FDC (Fasted) · ANOVA · p = <0.0001 · Adjusted geometric mean ratio (%): 96.49 · 90% CI 93.758 to 99.311Ratio calculated as Empa/ 1500 mg Met FDC (Fasted) divided by Empa/ 1500 mg Glumetza® (Fasted)
PrimaryCmax (Maximum Measured Concentration of the Analyte in Plasma, for Empagliflozin

Maximum measured concentration of empagliflozin in plasma (Cmax).

Time frame:
1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 20min, 1h 40min, 2h, 2.5h, 3h, 4h, 5h, 6h, 7h, 8h, 9h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration
Reported as:
Geometric mean · nmol/L
Cmax (Maximum Measured Concentration of the Analyte in Plasma, for Empagliflozin
nmol/LEmpa/1000 mg Glumetza® (Fasted)Empa/ 1000 mg Met FDC (Fasted)Empa/1000 mg Glumetza ® (Fed)Empa/ 1000 mg Met FDC (Fed)Empa/ 1500 mg Glumetza® (Fasted)Empa/ 1500 mg Met FDC (Fasted)
Cmax (Maximum Measured Concentration of the Analyte in Plasma, for Empagliflozin377 ± 22.5395 ± 24.6273 ± 27.6277 ± 31.0396 ± 21.9381 ± 22.0
Statistical analysis
  • Empa/1000 mg Glumetza® (Fasted) vs Empa/ 1000 mg Met FDC (Fasted) · ANOVA · p = <0.0001 · Adjusted geometric mean ratio (%): 104.83 · 90% CI 99.522 to 110.412Ratio calculated as Empa/ 1000 mg Met FDC (Fasted) divided by Empa/1000 mg Glumetza® (Fasted)
  • Empa/1000 mg Glumetza ® (Fed) vs Empa/ 1000 mg Met FDC (Fed) · ANOVA · p = <0.0001 · Adjusted geometric mean ratio (%): 101.84 · 90% CI 95.030 to 109.134Ratio calculated as Empa/ 1000 mg Met FDC (Fed) divided by Empa/1000 mg Glumetza ® (Fed)
  • Empa/ 1500 mg Glumetza® (Fasted) vs Empa/ 1500 mg Met FDC (Fasted) · ANOVA · p = <0.0001 · Adjusted geometric mean ratio (%): 96.03 · 90% CI 90.217 to 102.211Ratio calculated as Empa/ 1500 mg Met FDC (Fasted) divided by Empa/ 1500 mg Glumetza® (Fasted)
PrimaryCmax (Maximum Measured Concentration of the Analyte in Plasma, for Metformin

Maximum measured concentration of metformin in plasma

Time frame:
1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 20min, 1h 40min, 2h, 2.5h, 3h, 4h, 5h, 6h, 7h, 8h, 9h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration
Reported as:
Geometric mean · ng/mL
Cmax (Maximum Measured Concentration of the Analyte in Plasma, for Metformin
ng/mLEmpa/1000 mg Glumetza® (Fasted)Empa/ 1000 mg Met FDC (Fasted)Empa/1000 mg Glumetza ® (Fed)Empa/ 1000 mg Met FDC (Fed)Empa/ 1500 mg Glumetza® (Fasted)Empa/ 1500 mg Met FDC (Fasted)
Cmax (Maximum Measured Concentration of the Analyte in Plasma, for Metformin975 ± 37.2964 ± 39.91110 ± 21.21200 ± 22.71220 ± 32.81270 ± 34.7
Statistical analysis
  • Empa/1000 mg Glumetza® (Fasted) vs Empa/ 1000 mg Met FDC (Fasted) · ANOVA · p = 0.0027 · Adjusted geometric mean ratio (%): 98.94 · 90% CI 87.925 to 111.329Ratio calculated as Empa/ 1000 mg Met FDC (Fasted) divided by Empa/1000 mg Glumetza® (Fasted)
  • Empa/1000 mg Glumetza ® (Fed) vs Empa/ 1000 mg Met FDC (Fed) · ANOVA · p = <0.0001 · Adjusted geometric mean ratio (%): 108.18 · 90% CI 102.792 to 113.859Ratio calculated as Empa/ 1000 mg Met FDC (Fed) divided by Empa/1000 mg Glumetza ® (Fed)
  • Empa/ 1500 mg Glumetza® (Fasted) vs Empa/ 1500 mg Met FDC (Fasted) · ANOVA · p = 0.0060 · Adjusted geometric mean ratio (%): 103.62 · 90% CI 92.116 to 116.559Ratio calculated as Empa/ 1500 mg Met FDC (Fasted) divided by Empa/ 1500 mg Glumetza® (Fasted)
SecondaryAUC0-infinity (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity), for Metformin

Area under the concentration-time curve of metformin in plasma over the time interval from 0 extrapolated to infinity

Time frame:
1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 20min, 1h 40min, 2h, 2.5h, 3h, 4h, 5h, 6h, 7h, 8h, 9h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration
Reported as:
Geometric mean · ng*h/mL
AUC0-infinity (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity), for Metformin
ng*h/mLEmpa/1000 mg Glumetza® (Fasted)Empa/ 1000 mg Met FDC (Fasted)Empa/1000 mg Glumetza ® (Fed)Empa/ 1000 mg Met FDC (Fed)Empa/ 1500 mg Glumetza® (Fasted)Empa/ 1500 mg Met FDC (Fasted)
AUC0-infinity (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity), for Metformin7480 ± 37.47360 ± 36.713900 ± 20.713600 ± 20.410500 ± 28.510900 ± 28.7
Statistical analysis
  • Empa/1000 mg Glumetza® (Fasted) vs Empa/ 1000 mg Met FDC (Fasted) · ANOVA · p = 0.0008 · Adjusted geometric mean ratio (%): 98.33 · 90% CI 89.13 to 108.47Ratio calculated as Empa/ 1000 mg Met FDC (Fasted) divided by Empa/1000 mg Glumetza® (Fasted)
  • Empa/1000 mg Glumetza ® (Fed) vs Empa/ 1000 mg Met FDC (Fed) · ANOVA · p = <0.0001 · Adjusted geometric mean ratio (%): 98.71 · 90% CI 94.77 to 102.80Ratio calculated as Empa/ 1000 mg Met FDC (Fed) divided by Empa/1000 mg Glumetza ® (Fed)
  • Empa/ 1500 mg Glumetza® (Fasted) vs Empa/ 1500 mg Met FDC (Fasted) · ANOVA · p = 0.0021 · Adjusted geometric mean ratio (%): 103.90 · 90% CI 94.09 to 114.74Ratio calculated as Empa/ 1500 mg Met FDC (Fasted) divided by Empa/ 1500 mg Glumetza® (Fasted)

Adverse events

Collected over From drug administration until next treatment period or follow-up visit, 10 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Empa/1000 mg Glumetza® (Fasted)—0/24 (0%)4/24 (16.7%)
Empa/ 1000 mg Met FDC (Fasted)—0/24 (0%)5/24 (20.8%)
Empa/1000 mg Glumetza ® (Fed)—0/24 (0%)4/24 (16.7%)
Empa/ 1000 mg Met FDC (Fed)—0/24 (0%)4/24 (16.7%)
Empa/ 1500 mg Glumetza® (Fasted)—0/24 (0%)6/24 (25%)
Empa/ 1500 mg Met FDC (Fasted)—0/23 (0%)7/23 (30.4%)
Most frequent other events
Most frequent other events
EventEmpa/1000 mg Glumetza® (Fasted)Empa/ 1000 mg Met FDC (Fasted)Empa/1000 mg Glumetza ® (Fed)Empa/ 1000 mg Met FDC (Fed)Empa/ 1500 mg Glumetza® (Fasted)Empa/ 1500 mg Met FDC (Fasted)
DiarrhoeaGastrointestinal disorders2/242/240/242/240/244/23
NauseaGastrointestinal disorders0/241/244/242/241/241/23
Abdominal painGastrointestinal disorders0/241/240/241/243/242/23
DizzinessNervous system disorders1/242/240/240/242/242/23
Oropharyngeal painRespiratory, thoracic and mediastinal disorders2/240/240/240/240/240/23

Baseline characteristics

Treated set which included all subjects who were dispensed study medication and were documented to have taken at least one dose of study drug.

Age, Continuous
Age, Continuous(years)1000mg, Fasted1000mg, Fed1500mg, FastedTotal
Mean28.5 ± 8.732.4 ± 9.131.3 ± 8.730.7 ± 8.9
Sex: Female, Male
Sex: Female, Male(Participants)1000mg, Fasted1000mg, Fed1500mg, FastedTotal
Female16161648
Male88824
08

Study locations

1 site
  • Boehringer Ingelheim Investigational Site
    Austin, Texas, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2014, a primary completion of Jun 2014 and a completion of Jul 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2017, 2 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2014
First posted
Apr 8, 2014
Start
Apr 2014
Primary completionActual
Jun 2014
CompletionActual
Jul 2014
Results first posted
Mar 9, 2017
Last update
Mar 9, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 9, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02106923
Responsible party
Sponsor
First posted
Apr 8, 2014
Start date
Apr 2014
Primary completion
Jun 2014
Completion
Jul 2014
Results posted
Mar 9, 2017
Last update
Mar 9, 2017

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Empagliflozin · Metformin

Start the discussion